<DOC>
	<DOCNO>NCT01087021</DOCNO>
	<brief_summary>Primary Objective : - To assess potential effect QTcF interval ( QTc Fridericia ) cabazitaxel cancer patient Secondary Objectives : - To assess effect cabazitaxel heart rate ( HR ) , QT , QTcB ( Bazett 's correction ) , QTcN ( population specific correction ) intervals - To assess clinical safety cabazitaxel - To assess cabazitaxel plasma concentration Cycle 1 early timepoints ( infusion 5h post end infusion )</brief_summary>
	<brief_title>Effect Cabazitaxel QTc Interval Cancer Patients</brief_title>
	<detailed_description>The main period study consist maximum 21-day screening phase , first 2 treatment cycle cabazitaxel . End main period Cycle 3 30 day last dose patient discontinues study 1 2 treatment cycle . The duration patient main period study 9 10 week ( screen , 2 cycle ) . After Cycle 2 , patient option continue receive cabazitaxel follow safety report 30 day last dose cabazitaxel .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm solid malignancy metastatic unresectable , standard curative measure exist , treatment novel taxane agent consider . Exclusion criterion : Conditions screen ECG repolarization difficult interpret , show significant abnormality . This include , limited : high degree AV block , pacemaker , atrial fibrillation flutter QTcF &gt; 480 msec screen Electrocardiogram ( ECG ) Significant hypokalemia screening ( serum potassium &lt; 3.5 mMol/L ) Significant hypomagnesemia screening ( serum magnesium &lt; 0.7 mMol/L ) ( Note : Patient may enrol correction laboratory abnormality ) Patient receive ( discontinue ) , schedule receive QTprolonging drug The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>